

KidneyCARE Study

Community Access to Research Equity™

Community Update | April 2026



KidneyCARE Study Newsletter: Your Latest Kidney Health News

Dear KidneyCARE Study Community,

Thank you for being a part of the KidneyCARE Study to advance kidney research. Since March 2024, the Study has grown to include almost 3,000 participants nationwide. We thank you for your continued commitment to the KidneyCARE Study and look forward to sharing the data we have gathered soon.

In this issue, you will find resources for financial support for medications, a clinical trial opportunity, a podcast on the importance of diversity in clinical trials, and new kidney research.

New Kidney Health Resource

Many people living with kidney disease use medications to help manage their kidney disease. The National Kidney Foundation (NKF) offers a resource to help identify financial support or resources to help pay for medications. To learn more about prescription assistance, copay programs, and organizations that help people with kidney disease lower their medication costs, click [here](#).

In this Issue:

Here's what we are covering inside this newsletter. Click on any of the topics listed below for more information

- [New Kidney Health Resource](#)
- [Clinical Trial Opportunity for People Living with Diabetic Kidney Disease](#)
- [Hot Topics in Kidney Health Podcast](#)
- [Recent Kidney Research News](#)
- [Advocacy Highlight](#)
- [Frequently Asked Questions](#)

Questions? Comments?

Email: KidneyCareStudy@kidney.org
Phone: 212.889.2210 x134

KidneyCARE Study

Community Access to Research Equity™

Clinical Trial Spotlight

The PROACT 1 (REGEN-006) Study

The PROACT 1 Study is testing an investigational treatment called rilparencel for people with Advanced Chronic Kidney Disease and Type 2 Diabetes. Rilparencel is prepared from a participant's own kidney cells, collected by a doctor through a routine kidney biopsy procedure, for injection back into the kidneys. The study is evaluating whether rilparencel may help preserve kidney function and delay dialysis for people with Chronic Kidney Disease and Type 2 Diabetes.

To be eligible for the study, participants must meet at least the following criteria:

- Have a diagnosis of Advanced Chronic Kidney Disease and Type 2 Diabetes.
- Be between 30 and 80 years of age
- Have HbA1C<9.5%
- Have kidney function within specific ranges:
 - eGFR ≥ 20 and < 30 mL/min/1.73m² AND UACR ≤ 5000 mg/g); OR
 - eGFR of 30 to ≤ 35 mL/min/1.73m² AND UACR of 300 to ≤ 5000 mg/g
- Not have had a kidney transplant or be on dialysis

If you meet these criteria, additional screening will be required to confirm whether you are eligible to participate.

To learn more and participate:

Visit the [PROACT 1 Study website](#) for more information.

The website features a “Join the Trial” section where you can fill out an online screening. If you qualify based on your responses, a representative will reach out to you directly to provide a referral to a study site.

Please note that this study involves in-person visits, so you must be able to travel to a study site for study visits and procedures. Travel to the sites may be reimbursed for both patients and caregivers.

KidneyCARE Study

Community Access to Research Equity™



Recent Kidney Research News

The FIND-CKD Study:

Clinical trials are important for advancing kidney disease treatments and care. This recent clinical trial demonstrates ongoing advances in care.

The FIND-CKD is the largest phase III study to date focused on non-diabetic CKD. Results have shown improvement for people living with non-diabetic kidney disease who took the medication KERENDIA® (finerenone). Participants in the clinical trial showed a statistically significant improvement in the estimated glomerular filtration rate (eGFR) slope during the clinical trial. These findings offer hope for another treatment possibility for those living with non-diabetic kidney disease. Learn more [here](#).

NKF KDOQI Clinical Practice Guidelines:

The NKF Kidney Disease Outcomes Quality Initiative (NKF KDOQI) supports kidney care guidelines to improve patient-centered quality measures.

In March, the NKF KDOQI released two commentaries to support more holistic, equitable, and effective care for individuals and families affected by ADPKD (Autosomal Dominant Polycystic Kidney Disease). Published in the American Journal of Kidney Diseases, these commentaries highlight expert clinical guidance and patients' experiences of living with ADPKD.

The first commentary includes clinical recommendations on diagnosis, management of kidney and non-kidney aspects of the disease, CKD progression factors, and disease-modifying therapies.

The second commentary includes real world perspectives from people living with ADPKD and caregivers impacted by ADPKD. This commentary highlights priorities that matter most to people living with ADPKD and their families, including shared decision-making, mental and emotional health, care coordination, and clear communication across specialties.

To learn more and read the clinical and patient perspective commentaries, click [here](#).

Hot Topics in Kidney Health Podcast

The NKF recently hosted a Hot Topics in Kidney Health Podcast regarding the importance of diversity in clinical trials. The discussion focused on why being a part of a clinical trial is important, and why your participation in clinical trials can lead to better treatments for kidney disease. Learn more about clinical trials by listening [here](#).

KidneyCARE Study

Community Access to Research Equity™



Advocacy Highlight

The NKF continues to promote action for policy reform for prevention and treatment of kidney disease.

Following the recent House Ways and Means Health Subcommittee hearing “Improving Kidney Health Through Better Prevention and Innovative Treatment,” NKF is urging policymakers to accelerate reforms that prioritize prevention, early diagnosis, and access to cost-effective treatment options. Key priorities include early detection of kidney disease, expanded access to kidney transplantation, improved access to home dialysis and patient-centered care options, improved Medicare payment policies, and barriers to accessing kidney care. You can learn more about these policy efforts [here](#).

To learn more about what NKF is doing to advocate for kidney patients in Congress and with the Administration, click [here](#).

Frequently Asked Questions

Q: How do I access my verification code when I log back into my KidneyCARE Study account?

A: Here are the steps for logging into your KidneyCARE Study account

1. Go to kidneycarestudy.org
2. Click on login
3. You will automatically be redirected to the <https://kidneycarestudy.org/login-patient> page
4. Put in your email and password
5. A message should pop up stating you have received an activation code to your email. Do not close this tab/page to check your email, instead open a new tab/page to get to your email
6. Check your email for this code. Copy this code. This code does expire in 10 minutes, so if it takes longer than 10 minutes to access your email and get the code, the code does expire
7. Go back to the page that you still have open to put in your code. This will allow you access to the main page of the KidneyCARE study, the educational benefits, and the surveys

Questions? Comments?

Email: KidneyCareStudy@kidney.org
Phone: 212.889.2210 x134